Fugen Wu Selected Research

CRTH2 antagonist CT-133

7/2019

A CRTH2 antagonist, CT-133, suppresses NF-κB signalling to relieve lipopolysaccharide-induced acute lung injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fugen Wu Research Topics

Disease

3	Lung Injury 07/2019 - 07/2016
3	Acute Lung Injury 07/2019 - 01/2017
2	Inflammation (Inflammations) 01/2017 - 07/2016
1	Hypoxia (Hypoxemia) 07/2019
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 07/2019
1	Neonatal Sepsis 12/2018
1	Sepsis (Septicemia) 12/2018
1	Pulmonary Edema 01/2017
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2017
1	Pneumonia (Pneumonitis) 01/2017

Drug/Important Bio-Agent (IBA)

3	LipopolysaccharidesIBA 07/2019 - 07/2016
1	Evans Blue (Blue, Evans)FDA Link 07/2019
1	CRTH2 antagonist CT-133IBA 07/2019
1	AlbuminsIBA 07/2019
1	Peroxidase (Myeloperoxidase)IBA 07/2019
1	Prostaglandin D2IBA 07/2019
1	Interleukin-6 (Interleukin 6)IBA 07/2019
1	ProstaglandinsIBA 01/2019
1	SmokeIBA 01/2019
1	Nicotinamide PhosphoribosyltransferaseIBA 12/2018
1	MicroRNAs (MicroRNA)IBA 12/2018
1	Myosin-Light-Chain KinaseIBA 01/2017
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	ML 7IBA 01/2017
1	Caspase 9IBA 01/2017
1	bcl-2-Associated X Protein (bcl 2 Associated X Protein)IBA 01/2017
1	GlycogenIBA 01/2017
1	GinkgolidesIBA 07/2016
1	ginkgolide BIBA 07/2016

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 07/2019